Literature DB >> 1353144

Psychological and social consequences of community carrier screening programme for cystic fibrosis.

E K Watson1, E S Mayall, J Lamb, J Chapple, R Williamson.   

Abstract

We have assessed the effect of screening for cystic fibrosis (CF) carrier status on anxiety levels, attitudes, knowledge and actions of participants in a pilot programme conducted through primary health care services. Over 3000 individuals were screened and 100 carriers with no previous family history were identified. Varying degrees of anxiety were found to be associated initially with a positive result, but most of this was allayed by genetic counselling, and we find no adverse long-term psychological consequences in carriers. Most discussed carrier status with their partner (89%), parents, other relatives and also with friends; 87% of partners to whom testing was suggested have been screened. Those testing positive indicated that knowledge of carrier status would be considered in future reproductive decisions, and after 6 months carriers retained a reasonable level of knowledge about CF and its inheritance. Carriers and non-carriers uniformly approve of screening and are glad to have been tested. Knowledge of CF in the sample of non-carriers has also increased after testing, suggesting screening may improve understanding of CF among the entire target population. Fears of possible social costs of screening may be ill-founded.

Entities:  

Keywords:  Empirical Approach; Genetics and Reproduction; Health Care and Public Health

Mesh:

Year:  1992        PMID: 1353144     DOI: 10.1016/0140-6736(92)90477-k

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  21 in total

1.  Carrier testing of children for two X linked diseases in a family based setting: a retrospective long term psychosocial evaluation.

Authors:  O Järvinen; A M Aalto; A E Lehesjoki; M Lindlöf; I Söderling; A Uutela; H Kääriäinen
Journal:  J Med Genet       Date:  1999-08       Impact factor: 6.318

2.  Implications of carrier identification in newborn screening for cystic fibrosis.

Authors:  E P Parsons; A J Clarke; D M Bradley
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-11       Impact factor: 5.747

3.  Cystic fibrosis carrier population screening in the primary care setting.

Authors:  S Loader; P Caldwell; A Kozyra; J C Levenkron; C D Boehm; H H Kazazian; P T Rowley
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

Review 4.  Can we make assumptions about the psychosocial impact of living as a carrier, based on studies assessing the effects of carrier testing?

Authors:  Celine Lewis; Heather Skirton; Ray Jones
Journal:  J Genet Couns       Date:  2010-09-29       Impact factor: 2.537

5.  A comparison of two approaches to education about carrier testing for cystic fibrosis.

Authors:  K P Leonard; L K Bartholomew; P R Swank; G S Parcel
Journal:  J Genet Couns       Date:  1995-06       Impact factor: 2.537

6.  Attitudes of potential providers towards preconceptional cystic fibrosis carrier screening.

Authors:  Francis A M Poppelaars; Herman J Adèr; Martina C Cornel; Lidewij Henneman; Rosella P M G Hermens; Gerrit van der Wal; Leo P ten Kate
Journal:  J Genet Couns       Date:  2004-02       Impact factor: 2.537

7.  Acceptability of carrier screening for cystic fibrosis during pregnancy in a German population.

Authors:  U Jung; U Urner; K Grade; C Coutelle
Journal:  Hum Genet       Date:  1994-07       Impact factor: 4.132

8.  Testing carrier status in siblings of patients with cystic fibrosis.

Authors:  I Balfour-Lynn; S Madge; R Dinwiddie
Journal:  Arch Dis Child       Date:  1995-02       Impact factor: 3.791

9.  Cystic fibrosis heterozygote screening in 5,161 pregnant women.

Authors:  D R Witt; C Schaefer; P Hallam; S Wi; B Blumberg; A Fishbach; J Holtzman; S Kornfeld; R Lee; L Nemzer; R Palmer
Journal:  Am J Hum Genet       Date:  1996-04       Impact factor: 11.025

10.  Screening for carriers of cystic fibrosis--a general practitioner's perspective.

Authors:  M Modell
Journal:  BMJ       Date:  1993-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.